Ascendiant Capital Maintains Buy on Aclarion, Lowers Price Target to $7
3/25/2026
Impact: -60
Healthcare
Ascendiant Capital analyst Lucas Ward has maintained a 'Buy' rating on Aclarion (NASDAQ: ACON) but has lowered the price target from $23 to $7. This adjustment reflects a significant decrease in the expected valuation of the company.
AI summary, not financial advice
Share: